Asano-Mori Yuki
Department of Hematology, Toranomon Hospital.
Rinsho Ketsueki. 2016;57(10):2208-2217. doi: 10.11406/rinketsu.57.2208.
Invasive fungal infections (IFIs) are one of the most serious complications developing after allogeneic hematopoietic stem cell transplantation (allo-HSCT). They are difficult to treat once present and usually have a fatal course in profoundly immunosuppressed patients. Upfront prevention therefore plays an important role in overcoming this threat. The combination of a protected environment and antifungal prophylaxis against Candida spp. is conventionally applied to prevent IFIs during the neutropenic period after HSCT, whereas mold-active agents are recommended for prophylaxis against Aspergillus spp. in the later period when high-dose steroids are frequently used for the treatment of graft-versus-host disease (GVHD). However, advances in transplantation technology have made the risk of IFIs more diverse and complex. Preventive strategies should be planned using the patient's background and surrounding environment as a guide for accurate evaluation of individual risks, and should also be revised to fit time-dependent changes in the patient's immune status and condition after HSCT. Sufficient knowledge of the properties of antifungal agents is also essential for maintaining the balance between the efficacy and the toxicity of the prophylaxis over time.
侵袭性真菌感染(IFI)是异基因造血干细胞移植(allo-HSCT)后发生的最严重并发症之一。一旦发生,治疗困难,在免疫功能严重低下的患者中通常会导致致命后果。因此,早期预防在应对这一威胁中起着重要作用。传统上,在HSCT后的中性粒细胞减少期,采用保护环境和抗念珠菌属真菌预防措施相结合的方法来预防IFI,而在后期,当高剂量类固醇常用于治疗移植物抗宿主病(GVHD)时,推荐使用抗曲霉菌属霉菌活性药物进行预防。然而,移植技术的进步使IFI的风险更加多样和复杂。应根据患者背景和周围环境,以准确评估个体风险为指导制定预防策略,并且还应根据HSCT后患者免疫状态和病情随时间的变化进行调整。充分了解抗真菌药物的特性对于长期维持预防效果与毒性之间的平衡也至关重要。